  <pharmacology>
    <!-- This is a library of drug parameters and treatment schedules
    parameterised for OpenMalaria. All drug parameters were provided by
    Katherine Kay (LSTM); schedules and dosage information has varying sources.
    
    This library can be copied into the relevant section of a scenario
    document. Unused drugs, schedules and dosages may (if desired) be deleted.
    -->
    <treatments>
      <schedule name="AL_full">
        <!-- Recommended Artemether-Lumefantrine dosing schedule. -->
        <!-- Dose sizes are single tablets; the separate dosage table lists -->
        <!-- the number of tablets recommended. -->
        <!-- Source: WHO / Novartis product information -->
        <medicate drug="AR" hour="0" mg="20"/>
        <medicate drug="LF" hour="0" mg="120"/>
        <medicate drug="AR" hour="8" mg="20"/>
        <medicate drug="LF" hour="8" mg="120"/>
        <medicate drug="AR" hour="24" mg="20"/>
        <medicate drug="LF" hour="24" mg="120"/>
        <medicate drug="AR" hour="36" mg="20"/>
        <medicate drug="LF" hour="36" mg="120"/>
        <medicate drug="AR" hour="48" mg="20"/>
        <medicate drug="LF" hour="48" mg="120"/>
        <medicate drug="AR" hour="60" mg="20"/>
        <medicate drug="LF" hour="60" mg="120"/>
      </schedule>
      <schedule name="AL_bad_adherence">
        <medicate drug="AR" hour="0" mg="20"/>
        <medicate drug="LF" hour="0" mg="120"/>
      </schedule>
      <schedule name="AS">
        <!-- TODO: what is this? Artesunate IV? Are doses in mg/kg? -->
        <medicate drug="AS" duration="0.001" hour="0" mg="2.4"/>
        <medicate drug="AS" duration="0.001" hour="12" mg="2.4"/>
        <medicate drug="AS" duration="0.001" hour="24" mg="2.4"/>
        <medicate drug="AS" duration="0.001" hour="48" mg="2.4"/>
        <medicate drug="AS" duration="0.001" hour="72" mg="2.4"/>
      </schedule>
      <dosages name="AL_age">
        <!-- This dosing information was provided by Valerie Crowell; not sure of source -->
        <age lowerbound="0" dose_mult="1"/>
        <age lowerbound="3" dose_mult="2"/>
        <age lowerbound="9" dose_mult="3"/>
        <age lowerbound="15" dose_mult="4"/>
      </dosages>
      <dosages name="AL_mass">
        <!-- Source: WHO / Novartis product information -->
        <!-- Note: there is no recommended dose for <5kg, but WHO guidelines
          are to use (certain) ACTs anyway. -->
        <bodymass lowerbound="0" dose_mult="1"/>
        <bodymass lowerbound="15" dose_mult="2"/><!-- 2 tablets -->
        <bodymass lowerbound="25" dose_mult="3"/><!-- 3 tablets -->
        <bodymass lowerbound="35" dose_mult="4"/><!-- 4 tablets. -->
        <!-- Note: WHO points out there is a lack of evidence about dosing
          large adults, thus does not recommend higher doses. -->
      </dosages>
      <dosages name="AS">
        <!-- TODO: what is this? Artesunate IV with some units? -->
        <age lowerbound="0" dose_mult="1"/>
      </dosages>
    </treatments>
    <drugs>
      <drug abbrev="AR"><!-- Artemether -->
        <PD>
          <phenotype name="sensitive">
            <max_killing_rate>27.6</max_killing_rate>
            <IC50>0.0023</IC50>
            <slope>4</slope>
          </phenotype>
        </PD>
        <PK>
          <negligible_concentration>0.000023</negligible_concentration>
          <half_life>0.175</half_life>
          <vol_dist>17.4</vol_dist>
        </PK>
      </drug>
      <drug abbrev="AS"><!-- Artesunate -->
        <PD>
          <phenotype name="sensitive">
            <max_killing_rate>27.6</max_killing_rate>
            <IC50>0.0016</IC50>
            <slope>4</slope>
          </phenotype>
        </PD>
        <PK>
          <negligible_concentration>0.000016</negligible_concentration>
          <half_life>0.042</half_life>
          <vol_dist>2.75</vol_dist>
        </PK>
      </drug>
      <drug abbrev="DHA"><!-- Dihydroartemisinin -->
        <PD>
          <phenotype name="sensitive">
            <max_killing_rate>27.6</max_killing_rate>
            <IC50>0.009</IC50>
            <slope>4</slope>
          </phenotype>
        </PD>
        <PK>
          <negligible_concentration>0.000016</negligible_concentration>
          <half_life>0.035</half_life>
          <vol_dist>1.49</vol_dist>
        </PK>
      </drug>
      <drug abbrev="CQ"><!-- Chloroquine -->
        <PD>
          <phenotype name="sensitive">
            <max_killing_rate>3.45</max_killing_rate>
            <IC50>0.02</IC50>
            <slope>1.6</slope>
          </phenotype>
        </PD>
        <PK>
          <negligible_concentration>0.00036</negligible_concentration>
          <half_life>30.006</half_life>
          <vol_dist>300</vol_dist>
        </PK>
      </drug>
      <drug abbrev="LF"><!-- Lumefantrine -->
        <PD>
          <phenotype name="sensitive">
            <max_killing_rate>3.45</max_killing_rate>
            <IC50>0.032</IC50>
            <slope>4</slope>
          </phenotype>
        </PD>
        <PK>
          <negligible_concentration>0.00032</negligible_concentration>
          <half_life>4.332</half_life>
          <vol_dist>21</vol_dist>
        </PK>
      </drug>
      <drug abbrev="MQ"><!-- Mefloquine -->
        <PD>
          <phenotype name="sensitive">
            <max_killing_rate>3.45</max_killing_rate>
            <IC50>0.027</IC50>
            <slope>5</slope>
          </phenotype>
        </PD>
        <PK>
          <negligible_concentration>0.005</negligible_concentration>
          <half_life>13.078</half_life>
          <vol_dist>20.8</vol_dist>
        </PK>
      </drug>
      <drug abbrev="PPQ"><!-- Piperaquine -->
        <PD>
          <phenotype name="sensitive">
            <max_killing_rate>3.45</max_killing_rate>
            <IC50>0.088</IC50>
            <slope>6</slope>
          </phenotype>
        </PD>
        <PK>
          <negligible_concentration>0.005</negligible_concentration>
          <half_life>23.105</half_life>
          <vol_dist>150</vol_dist>
        </PK>
      </drug>
    </drugs>
  </pharmacology>
